The Longevity Revolution

Living longer than your plan

The greatest risk to your retirement may not be market volatility. It might be underestimating how long, and how well, you are going to live.

For decades, retirement planning has rested on a simple formula: work hard, build a nest egg, and prepare for a gradual winding down across a 15 to 20 year off ramp.

But sitting at the intersection of early-stage technology and venture capital at Ascension, I get a front-row seat to the innovations shaping the next decade. And from where I sit, that traditional off ramp is rapidly disappearing.

Instead of winding down, the next generation of retirees may be winding up: living longer, healthier, and with more physical vitality than any generation in history.

We are standing at a convergence of healthcare and technology that could fundamentally alter human longevity.

Here are three shifts rewriting the rules, and why it is worth rethinking what we are really investing for.

The macro view: AI and the breakthroughs of the next decade

The horizon of medicine is being redrawn by artificial intelligence.

Bringing a new drug to market has historically taken more than a decade and billions of pounds, bogged down by the trial and error of identifying molecular structures and testing how compounds behave in the body.

AI is collapsing those timelines.

DeepMind’s AlphaFold, which won the 2024 Nobel Prize in Chemistry, opened the floodgates for structural biology, and spin-outs like Isomorphic Labs are now using AI to design optimised therapeutic candidates from scratch.

The company raised $2.1bn in 2025, partnered with Novartis and Eli Lilly, and expects to put its first AI-designed drugs into human trials by the end of 2026.

A world where researchers can forecast how a drug behaves in the body before the first patient ever takes it is being built right now.

Over the next five to ten years we are moving towards automated drug discovery and simulated interaction testing, with credible estimates already suggesting AI could compress clinical trial timelines by 30 to 50 per cent.

The prize is a future where conditions that are chronic or even terminal today are managed, or solved, far faster than standard actuarial tables ever anticipated.

The same intelligence is being aimed at catching disease earlier, which is one of the highest-leverage ways to extend a healthy life.

This is not abstract for me; it is what we invest behind at Ascension.

One of our portfolio companies, Xgenera, is developing a blood test designed to detect a range of cancers at an early, more treatable stage, built on a panel of microRNA biomarkers read by machine learning.

The principle is simple:

The earlier we see a problem, the longer and better we live.

The mid-term reality: the metabolic shift

We do not have to wait a decade to see the revolution begin; it is already playing out in the pharmacy.

The rise of GLP-1 medicines like Ozempic, Wegovy and Mounjaro has transformed how society approaches weight and diabetes.

In early 2025, semaglutide became the first drug of its kind approved to slow kidney disease and reduce cardiovascular death in certain patients.

The benefits already reach well beyond the scales.

The next wave is more profound still.

Triple-receptor peptides like retatrutide, now in advanced clinical trials, do not just suppress appetite; they target glucagon receptors to raise energy expenditure and metabolic output.

In Phase 3 it delivered average weight loss of around 28 per cent, with nearly half of participants losing 30 per cent or more, edging towards results once only possible with surgery.

The downstream effects of a healthier population are staggering.

A lasting reduction in obesity-related conditions means far fewer cases of type 2 diabetes, cardiovascular disease and joint-replacement surgery.

The burden shifts from reactive healthcare, treating the sick, towards proactive wellness, easing the pressure on systems like the NHS.

Meanwhile the regulatory landscape in the United States is in flux, with the FDA reshaping its stance on longevity therapies and a wave of institutional capital racing to build scalable, cellular-level treatments.

A healthier population also depends on the food on its plate, and that supply chain is being reinvented too.

Another of our companies, Concert Bio, uses the plant microbiome to help indoor and soilless farms grow more resilient, nutritious crops with fewer inputs.

It is a reminder that healthspan does not start in the pharmacy; it starts with what we eat and how it is grown.

The immediate power: hyper-personalised medicine is already here

While global labs chase the next blockbuster, the power of personalised healthcare has already reached the consumer.

You no longer have to rely on generic medical advice.

This part of the future is not coming next year; it is on your desktop today.

I have experienced it firsthand.

For a few hundred pounds, I recently had my entire genome sequenced. I then fed that raw data into advanced, consumer-accessible AI models.

The results were striking.

Rather than surface-level ancestry, the AI cross-referenced my DNA against the published research to build a tailored health blueprint: a detailed read on my cellular predispositions, my nutritional needs, and the specific risks worth watching.

If you understand what these tools can do, you can begin optimising your healthspan right now.

There is one more dimension to longevity that is easy to forget.

A long, healthy life is only worth as much as the world you get to live it in.

At Ascension we care about personal healthspan, but we also back the idea that the planet needs to be around, and in good health, for the long term.

That is why we have invested in Epoch Biodesign, a company engineering enzymes that quite literally break down plastic waste, turning one of the most stubborn pollutants of the modern age back into useful material.

Living longer is the goal; having somewhere worth living is the precondition.

The ultimate question: how long will your retirement be?

Combine AI-driven drug discovery, game-changing metabolic therapies, and immediate access to personalised genetic insight, and the conclusion is hard to avoid:

Human healthspan is catching up with human lifespan.

If you enter retirement strong, fit, sharp and metabolically vibrant, you are not facing a quiet wind-down.

You might start a business, pivot to a second career, travel hard, or pursue an active life well into your 80s and 90s.

And that changes everything about wealth planning.

• Longevity inflation: does your drawdown strategy protect your capital across a potential 35 to 40 year retirement?
• Asset allocation: are your investments structured to outpace the cost of a longer, more active lifestyle?
• The second act: have you planned your wealth not just to sustain old age, but to actively fund a dynamic, decades-long second chapter?

Health is the ultimate wealth.

But as science hands us the keys to a longer, healthier life, making your capital as resilient as your body becomes the real financial challenge.

It is time to stop planning for an ending, and start investing for a much longer story.

This article reflects the author’s personal views and is intended to provoke thought, not to predict outcomes.

It is not financial, investment, tax or medical advice, and nothing here is a recommendation.

This document is marketing material for a retail audience and does not constitute advice or recommendations. Past performance is not a guide to future performance and may not be repeated. The value of investments and the income from them may go down as well as up and investors may not get back the amount originally invested.